Your session is about to expire
← Back to Search
Oral Ifetroban for AERD
Study Summary
This trial will test ifetroban, a drug designed to treat AERD, is safe and effective. AERD is a disease that causes asthma, recurring nasal polyps, and respiratory reactions to aspirin and other nonsteroidal anti-inflammatory drugs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I haven't taken NSAIDs or drugs affecting the cyclooxygenase enzyme in the last two weeks.I have been part of a clinical trial for ifetroban within the last 3 months.I have been on allergy shots for less than 12 months or on certain allergy medications for less than a month.I had sinus surgery or polyp removal in the last 3 months.I have a condition that may affect the trial's outcome measurement.I have severe nasal symptoms as shown by my SNOT-22 score.I've had severe reactions to aspirin or similar drugs, including breathing problems.I haven't taken any immune-suppressing drugs in the last two weeks, except for long-term allergy shots or certain biologics.I have had nasal polyps.My asthma is stable, with no recent severe attacks or high-dose treatments.I haven't taken more than 20 mg of steroids daily in the last 4 weeks.I have been diagnosed with asthma by a doctor.I haven't used blood thinners or had bleeding problems in the last 2 weeks.I have been taking daily antihistamines for the last two weeks.You have been smoking tobacco every day for the past six months and have smoked at least once in the last three months.
- Group 1: Placebo Oral Capsule
- Group 2: Ifetroban Oral Capsule
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What risks are associated with Ifetroban Oral Capsule ingestion?
"Our team at Power gave Ifetroban Oral Capsule a score of 2 since it is still in Phase 2, so there has been some safety data collected but none for efficacy."
What is the breadth of medical institutions that are conducting this research?
"This research is recruiting participants at Vanderbilt University Medical Centre in Nashville, Advanced ENT & Allergy located in Louisville, and the University of Pennsylvania situated in Philadelphia. There are also 7 other sites joining this study."
Has this research ever been conducted before?
"The initial study of Ifetroban Oral Capsule, which was sponsored by Cumberland Pharmaceuticals and included 76 participants, commenced in 2017. Subsequently, the drug received Phase 2 approval. Currently, 4 active trials related to Ifetroban are being conducted across 27 cities and one nation."
What is the aggregate number of individuals participating in this trial?
"No longer actively enrolling patients, this clinical trial was initially posted on July 17th 2017 and last updated November 16th 2022. Those seeking medical studies can find 83 asthma trials and 4 Ifetroban Oral Capsule investigation currently recruiting participants."
Could you please elucidate any other experiments conducted on Ifetroban Oral Capsule?
"The pharmaceutical drug Ifetroban Oral Capsule was first investigated at Rochester Regional Health in 2017, with 37 trials having since come to a conclusion. Currently, four studies are underway; many of these occurring within the Nashville, Tennessee area."
Are there any vacancies left in this clinical experiment?
"It appears that the data hosted on clinicaltrials.gov indicates that this trial, which was posted in July of 2017 and last updated in November of 2022, is not actively recruiting patients at present. However, there are an additional 87 trials welcoming candidates currently."
Share this study with friends
Copy Link
Messenger